Watson supercomputer could have a place in future clinical setting

IBM's Jeopardy! winning supercomputer Watson will not likely replace your local doctor when you go in for a check-up, but it might not be so bad to have it around during your appointment.

Signs and symptoms of lymphoma are often so general that they don't set off alarm bells in the average clinician, and the process can up a lot of time with hits and misses, and end up either wasting precious time. Patients tend to assume their doctors are up to date on the latest medical information, but this would be impossible: the average clinician receives seven medical journals that feature 2,500 new articles every year. In order to stay on top of all this information, a doctor would need 80 hours a week just to read through it all.

Watson, on the other hand, processes information thanks to a technology known as Deep Question and Answer (DeepQA), which allows the computer to go through the equivalent of about one million books in three seconds. In other words, some in the medical community are eyeing Watson's ability to help clinicians make the most accurate diagnoses as soon as possible-- with your doctor on hand, of course.

Cancers-- and especially lymphomas-- are moving targets, with more and more learned about them every week. The average doctor can't keep up. A little on-hand help in the form of Watson wouldn't hurt.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap